Neurology

NEJM Journal Club

Questions discussed in this category

Is there a risk of CYP2C19 gene testing only being adopted by wealthier health systems, thereby creating a disparity gap in treatment?

What is the cost and accessibility of CYP2C19 gene testing? Does the limited availability of rapid genotyping techniques limit the clinical applicabil...

3 Answers available

Does the overall conclusion of the CHANCE-2 trial make ticagrelor + ASA a worthwhile transition given the data showing cumulative hazard of stroke diverged during the first week and was subsequently similar, which suggests the benefit of ticagrelor over clopidogrel is seen predominantly soon after stroke?

4 Answers available

Would you generalize the data from the CHANCE-2 trial to a broader clinic population given that the study was specific to Han Chinese patients?

How do you plan to incorporate the results of the CHANCE-2 trial (Wang et al., PMID 34708996) in your own practice?

3 Answers available

Do you recommend genetic testing after a patient on clopidogrel has a stroke based on the results of the CHANCE-2 trial?

3 Answers available

Papers discussed in this category

N Engl J Med, 2021 Oct 28

Ticagrelor versus Clopidogrel in Loss-of-Function Carriers with Stroke or TIA.

The New England journal of medicine, 2018-07-19

Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.

N Engl J Med, 2013 Jun 26

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

N Engl J Med,

Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.

Neurology

NEJM Journal Club

Questions discussed in this category

Papers discussed in this category

Related Topics in Neurology